Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Glaxo makes unsolicited offer to buy HGS for $2.6bn; now finalized

Executive Summary

GlaxoSmithKline PLC has made a hostile bid to acquire public top-tier biotech Human Genome Sciences Inc., which immediately rejected the $13-per-share offer (a 73% premium) valuing HGS at $2.6bn. HGS says it will be exploring strategic alternatives, including a possible sale, and did request additional information from GSK.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Includes Contract
    • Full Acquisition

Related Companies